A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN 6 - Long-term Outcomes)

Trial Profile

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN 6 - Long-term Outcomes)

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms SUSTAIN-6
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 13 Jun 2017 Results analysing effects of semaglutide on body weight over 2 years in patients with type 2 diabetes mellitus, presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 10 Jun 2017 Biomarkers information updated
    • 28 Feb 2017 According to a Novo Nordisk media release, based on the results from the SUSTAIN clinical trial programme, company has submitted NDA to the Japanese Ministry of Health, Labour and Welfare for semaglutide, administrated once-weekly, for the treatment of adults with type 2 diabetes. This filing follows the recent once-weekly semaglutide regulatory submissions to the US FDA, the European Medicines Agency (EMA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top